These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

353 related articles for article (PubMed ID: 37876726)

  • 1. Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study).
    Alrashed F; Abdullah I; Alfadhli A; Shehab M
    Front Pharmacol; 2023; 14():1243080. PubMed ID: 37876726
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn's disease in patients with prior failure of anti-tumour necrosis factor treatment.
    Hyun HK; Zhang HS; Yu J; Kang EA; Park J; Park SJ; Park JJ; Kim TI; Kim WH; Cheon JH
    BMC Gastroenterol; 2022 Mar; 22(1):143. PubMed ID: 35346063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab.
    Hu A; Kotze PG; Burgevin A; Tan W; Jess A; Li PS; Kroeker K; Halloran B; Panaccione R; Peyrin-Biroulet L; Ma C; Ananthakrishnan AN
    Clin Gastroenterol Hepatol; 2021 Jul; 19(7):1366-1376.e2. PubMed ID: 32668338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
    Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
    BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-Line Biologic Therapy Following Tumor Necrosis Factor Antagonist Failure: A Real-World Propensity Score-Weighted Analysis.
    Ibing S; Cho JH; Böttinger EP; Ungaro RC
    Clin Gastroenterol Hepatol; 2023 Sep; 21(10):2629-2638. PubMed ID: 36787837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Safety and Effectiveness of Biologic Therapy for Crohn's Disease: A CA-IBD Cohort Study.
    Singh S; Kim J; Luo J; Paul P; Rudrapatna V; Park S; Zheng K; Syal G; Ha C; Fleshner P; McGovern D; Sauk JS; Limketkai B; Dulai PS; Boland BS; Eisenstein S; Ramamoorthy S; Melmed G; Mahadevan U; Sandborn WJ; Ohno-Machado L
    Clin Gastroenterol Hepatol; 2023 Aug; 21(9):2359-2369.e5. PubMed ID: 36343846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ustekinumab or Vedolizumab after Failure of Anti-TNF Agents in Crohn's Disease: A Review of Comparative Effectiveness Studies.
    Sharip MT; Nishad N; Pillay L; Goordoyel N; Goerge S; Subramanian S
    J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673459
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent.
    Fumery M; Serrero M; Bouguen G; Amiot A; Altwegg R; Nachury M; Vuitton L; Treton X; Caillo L; Pereira B; Buisson A
    J Crohns Colitis; 2024 Oct; 18(10):1615-1621. PubMed ID: 38742654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of vedolizumab and ustekinumab in pediatric-onset inflammatory bowel disease: A real-world multicenter study.
    Rébus S; Coopman S; Djeddi D; Vanrenterghem A; Dupont C; Lacotte E; Ley D
    J Pediatr Gastroenterol Nutr; 2024 Oct; ():. PubMed ID: 39415517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.
    Ashraf H; Bodapati A; Hanif A; Okafor DK; Katyal G; Kaur G; Khan S
    Cureus; 2023 Nov; 15(11):e48338. PubMed ID: 38060699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of adverse clinical outcomes in patients with inflammatory bowel disease receiving different sequences of first- and second-line biologic treatments: findings from ROTARY.
    Krugliak Cleveland N; Ghosh S; Chastek B; Bancroft T; Candela N; Fan T; Umashankar K; Rubin DT
    BMC Gastroenterol; 2024 Sep; 24(1):314. PubMed ID: 39289603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study.
    Garcia-Romero R; Martinez de Zabarte Fernandez JM; Pujol-Muncunill G; Donat-Aliaga E; Segarra-Cantón O; Irastorza-Terradillos I; Medina-Benitez E; Ruiz-Hernández CJ; Carrillo-Palau M; Ros-Arnal I; Rodriguez-Martínez A; Escartin-Madurga L; Gutiérrez-Junquera C; Vicente-Santamaría S; Velasco Rodriguez-Belvis M; Fernández-Fernández S; Alberto-Alonso JR; Montraveta M; Torres-Peral R; Navalon-Rubio M; Navas-López VM; Martin de Carpi J
    Eur J Pediatr; 2021 Sep; 180(9):3029-3038. PubMed ID: 33880650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior treatment persistence with ustekinumab in Crohn's disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.
    Ko Y; Paramsothy S; Yau Y; Leong RW
    Aliment Pharmacol Ther; 2021 Aug; 54(3):292-301. PubMed ID: 34151447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
    Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor Necrosis Factor-alpha Exposure Impacts Vedolizumab Mucosal Healing Rates in Pediatric Inflammatory Bowel Disease.
    Jossen J; Kiernan BD; Pittman N; Dubinsky MC
    J Pediatr Gastroenterol Nutr; 2020 Mar; 70(3):304-309. PubMed ID: 31738290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No Benefit of Concomitant Immunomodulator Therapy on Efficacy of Biologics That Are Not Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases: A Meta-analysis.
    Yzet C; Diouf M; Singh S; Brazier F; Turpin J; Nguyen-Khac E; Meynier J; Fumery M
    Clin Gastroenterol Hepatol; 2021 Apr; 19(4):668-679.e8. PubMed ID: 32629124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn's Disease Initiating Vedolizumab Versus Ustekinumab.
    Kappelman MD; Lewis JD; Zhang X; Lin FC; Weisbein L; Chen W; Burris J; Dorand JE; Parlett LE; Haynes K; Nair V; Kaul AF; Dobes A; Long MD
    Dig Dis Sci; 2023 Aug; 68(8):3413-3420. PubMed ID: 37115362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
    Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
    Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of infection in elderly patients with inflammatory bowel disease under biologics: A prospective, multicenter, observational, one-year follow-up comparative study.
    Bozon A; Nancey S; Serrero M; Caillo L; Gilletta C; Benezech A; Combes R; Danan G; Akouete S; Pages L; Bourgaux JF; Le Cosquer G; Boivineau L; Meszaros M; Altwegg R
    Clin Res Hepatol Gastroenterol; 2023 May; 47(5):102107. PubMed ID: 36906225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy is not associated with improved rates of clinical or endoscopic remission in patients with inflammatory bowel disease treated with ustekinumab or vedolizumab: a retrospective study.
    Jeffrey AW; Picardo S; Menon S; So K; Venugopal K
    Ann Gastroenterol; 2023; 36(4):430-436. PubMed ID: 37396006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.